Go
to Main Home PageSummary:
Results of three months of Neuro-restorative therapy in twenty children, aged 2
to 4 years, with moderately severe Cerebral Palsy, given Unani / Ayurvedic drugs
for three months, starting one month after completing the sessions of Hyperbaric
Oxygen Therapy.
Last reviewed January 21, 2007
Results of 1st 20 children given
Unani Therapy in MMT of CP
|
Unani Therapy is a modern version of ancient Greek medicine, contributed heavily by Ayurveda and Rasayana Shastra of ancient India, supplemented by Arab medicine. One of the foremost exponents of Unani Therapy is Hamdard University of India, which has taken a lead to bring it up to modern standards in scientific study and standardization of products.
Hamdard University is helping UDAAN to develop a line of Unani formulations that may benefit a child with Neurodevelopmental delay. The first step in that direction came with standardization of the selected ingredients of the novel Neuro-restorative formulation. Then, it was used as a pilot project to treat two dozen or so small children as part of a Post Graduate Research Thesis. The results were encouraging as far as Cognitive Parameters were concerned.
Now, with the aid of the Ministry of Health, Government of India, a larger scale controlled study has started at UDAAN with an enhanced formulation based on the formulation used successfully in the first study.
The results given below are the summary results of benefits observed in Cognitive features in the first 20 children aged less than 5 years (usually 2 to 4 years), who received Unani / Ayurvedic Neuro-restorative Drugs during the 4th to the 6th month (3 months) of the six-month Multimode Therapy regimen at UDAAN. The children were examined at base (start of 4th month of the Multimode Therapy regimen), and then at monthly intervals for 3 months. The drug was used as a BID dosage. The level of benefit or Neurodevelopment was graded using a scale of 1 to 5 signifying increasing benefit. At each assessment interval, the number of children left in a particular grade was counted for each parameter.
The results suggest that the incorporation of Unani Neuro-restorative drugs to the Multimode Therapy regimen as a follow up, one month after completing HBOT, gave a further enhancement to the Cognitive improvement in the children treated. The number of children in each code group at each assessment period for each parameter tested, is given below.
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
1 |
1(5.0%) |
1(5.0%) |
0vs1 .000 |
||
|
2 |
10(50.0%) |
8(40.0%) |
2(10.0%) |
1(5.0%) |
0vs2 .000 |
|
3 |
7(35.0%) |
5(25.0%) |
10(50.0%) |
9(45.0%) |
0vs3 .001 |
|
4 |
2(10.0%) |
6(30.0%) |
7(35.0%) |
9(45.0%) |
1vs2 .023 |
|
5 |
1(5.0%) |
1(5.0%) |
1vs3 .000 |
||
| Total | 20 | 20 | 20 | 20 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
1 |
2(10.0%) |
2(10.0%) |
0vs1 .000 |
||
|
2 |
10(50.0%) |
5(25.0%) |
3(15.0%) |
1(5.0%) |
0vs2 .000 |
|
3 |
5(25.0%) |
8(40.0%) |
9(45.0%) |
11(55.0%) |
0vs3 .001 |
|
4 |
3(15.0%) |
4(20.0%) |
7(35.0%) |
7(35.0%) |
1vs2 .000 |
|
5 |
1(5.0%) |
1(5.0%) |
1(5.0%) |
1vs3 .000 |
|
|
Total |
20 |
20 |
20 |
20 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
0 |
8(40.0%) |
3(15.0%) |
1(5.0%) |
0vs1 .002 |
|
|
1 |
6(30.0%) |
8(40.0%) |
2(10.0%) |
2(10.0%) |
0vs2 .000 |
|
2 |
5(25.0%) |
7(35.0%) |
12(60.0%) |
12(60.0%) |
0vs3 .000 |
|
3 |
1(5.0%) |
2(10.0%) |
4(20.0%) |
5(25.0%) |
1vs2 .000 |
|
4 |
1(5.0%) |
1(5.0%) |
1vs3 .000 |
||
|
Total |
20 |
20 |
20 |
20 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
0 |
3(15.0%) |
2(10.0%) |
1(5.0%) |
1(5.0%) |
0vs1 .000 |
|
1 |
17(85.0%) |
18(90.0%) |
19(95.0%) |
19(95.0%) |
0vs2 .015 |
|
Total |
20 |
20 |
20 |
20 |
0vs3 .015 |
|
1vs2 .002 |
|||||
|
1vs3 .000 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
0 |
1(5.0%) |
1(5.0%) |
0vs1 .000 |
||
|
1 |
2(10.0%) |
1(5.0%) |
1(5.0%) |
0vs2 .000 |
|
|
2 |
10(50.0%) |
6(30.0%) |
4(20.0%) |
1(5.0%) |
0vs3 .000 |
|
3 |
6(30.0%) |
12(60.0%) |
13(65.0%) |
11(55.0%) |
1vs2 .000 |
|
4 |
1(5.0%) |
1(5.0%) |
2(10.0%) |
6(30.0%) |
1vs3 .003 |
|
5 |
1(5.0%) |
||||
|
Total |
20 |
20 |
20 |
20 |
|
|
N |
Minimum |
Maximum |
Mean |
S.deviation |
|
Duration of conc. 0Month |
20 |
2 |
30 |
9.35 |
8.512 |
|
Duration of conc. 1Month |
20 |
3 |
50 |
14.05 |
11.914 |
|
Duration of conc. 2Month |
20 |
4 |
60 |
17.95 |
14.325 |
|
Duration of conc. 3Month |
20 |
6 |
60 |
20.95 |
14.752 |
|
Valid |
20 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
1 |
4(20.0%) |
2(10.0%) |
1(5.0%) |
0vs1 .003 |
|
|
2 |
9(45.0%) |
5(25.0%) |
4(20.0%) |
3(15.0%) |
0vs2 .097 |
|
3 |
6(30.0%) |
10(50.0%) |
10(15.0%) |
6(30.0%) |
0vs3 .001 |
|
4 |
1(5.0%) |
3(15.0%) |
5(25.0%) |
10(15.0%) |
1vs2 .000 |
|
5 |
1(5.0%) |
1vs3 .055 |
|||
|
Total |
20 |
20 |
20 |
20 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
1 |
2(10.0%) |
0vs1 .008 |
|||
|
2 |
10(50.0%) |
7(35.0%) |
5(25.0%) |
3(15.0%) |
0vs2 .001 |
|
3 |
7(35.0%) |
10(35.0%) |
10(35.0%) |
8(40.0%) |
0vs3 .000 |
|
4 |
1(5.0%) |
3(15.0%) |
5(25.0%) |
8(40.0%) |
1vs2 .000 |
|
5 |
1(5.0%) |
1vs3 .001 |
|||
|
Total |
20 |
20 |
20 |
20 |
|
|
N |
Minimum |
Maximum |
Mean |
S.deviation |
|
Perseverance-0Month |
20 |
3 |
15 |
7.10 |
2.713 |
|
Perseverance-1Month |
20 |
5 |
20 |
9.10 |
4.051 |
|
Perseverance-2Month |
20 |
5 |
20 |
11.15 |
4.158 |
|
Perseverance-3Month |
20 |
10 |
30 |
15.80 |
5.569 |
|
Valid |
20 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
1 |
6(30.0%) |
6(30.0%) |
4(20.0%) |
3(15.0%) |
0vs1 .000 |
|
2 |
7(35.0%) |
2(10.0%) |
2(10.0%) |
3(15.0%) |
0vs2 .001 |
|
3 |
5(25.0%) |
7(35.0%) |
8(40.0%) |
6(30.0%) |
0vs3 .000 |
|
4 |
2(10.0%) |
5(25.0%) |
6(30.0%) |
5(25.0%) |
1vs2 .000 |
|
5 |
3(15.0%) |
1vs3 .000 |
|||
|
Total |
20 |
20 |
20 |
20 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
1 |
2(11.8%) |
1(5.9%) |
1(5.9%) |
1(5.9%) |
0vs1 .036 |
2 |
|
2(11.8%) |
1(5.9%) |
|
0vs2 .021 |
3 |
11(64.0%) |
3(17.6%) |
1(5.9%) |
2(11.8%) |
0vs3 .000 |
4 |
4(23.0%) |
11(64.0%) |
13(76.9%) |
9(52.9%) |
1vs2 .010 |
5 |
|
|
1(5.9%) |
5(29.4%) |
2vs3 .002 |
Total |
17 |
17 |
17 |
20 |
|
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
1 |
5(29.4%) |
4(23.5%) |
3(17.6%) |
1(5.9%) |
0vs1 .001 |
|
2 |
8(47.1%) |
9(52.9%) |
5(29.4%) |
3(17.6%) |
0vs2 .001 |
|
3 |
2(11.8%) |
2(11.8%) |
7(41.2%) |
11(64.7%) |
0vs3 .003 |
|
4 |
2(11.8%) |
2(11.8%) |
2(11.8%) |
2(11.8%) |
1vs2 .000 |
|
total |
17 |
17 |
17 |
17 |
1vs3 .000 |
|
Codes |
0-Month |
1-Month |
2-Month |
3-Month |
P value |
|
0 |
18(90.0%) |
13(65.0%) |
7(35.0%) |
5(25.0%) |
0vs1 .118 |
|
1 |
2(10.0%) |
14(20.0%) |
8(40.0%) |
8(40.0%) |
0vs2 0.57 |
|
2 |
|
3(15.0%) |
5(25.0%) |
7(35.0%) |
0vs3 .169 |
|
Total |
20 |
20 |
20 |
20 |
1vs2 .002 |
|
|
|
|
|
|
2vs3 .000 |
| Click here to go to top |